Heaney Liam G, McGarvey Lorcan P A
Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, UK.
Respiration. 2017;93(3):153-161. doi: 10.1159/000455395. Epub 2017 Jan 21.
Asthma and chronic obstructive pulmonary disease (COPD) are prevalent conditions, and despite recent advances and multiple available therapies and interventions, there remains a significant unmet clinical need. In recent years, it has become clear that there is both significant heterogeneity within each of these conditions and additionally significant overlap in many of the clinical and inflammatory features. In parallel, useful clinical and immunological biomarkers which inform about prognosis and response to therapy have emerged in both asthma and COPD. These biomarkers will allow both better targeting of existing treatments and the identification of those patients who will respond to novel therapies which are now becoming available. Biomarkers will also facilitate the identification of novel therapeutic targets for future development. Delivery of precision medicine in airways disease is now feasible and is a core component of a personalised healthcare delivery in asthma and COPD.
哮喘和慢性阻塞性肺疾病（COPD）是常见病症，尽管近年来取得了进展，有多种可用的治疗方法和干预措施，但仍存在重大的未满足的临床需求。近年来，很明显，在这些病症中的每一种内部都存在显著的异质性，而且在许多临床和炎症特征方面也有显著重叠。与此同时，在哮喘和COPD中都出现了有助于了解预后和治疗反应的有用的临床和免疫生物标志物。这些生物标志物将有助于更精准地使用现有治疗方法，并识别出那些对目前可用的新疗法有反应的患者。生物标志物还将促进识别未来开发的新治疗靶点。在气道疾病中实施精准医学现在是可行的，并且是哮喘和COPD个性化医疗服务的核心组成部分。
